Please use this identifier to cite or link to this item:
|Title:||Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics||Authors:||Jayaraman, R.
|Issue Date:||Dec-2011||Citation:||Jayaraman, R., Reddy, V.P., Pasha, M.K., Wang, H., Sangthongpitag, K., Yeo, P., Hu, C.Y., Wu, X., Xin, L., Goh, E., New, L.S., Ethirajulu, K. (2011-12). Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metabolism and Disposition 39 (12) : 2219-2232. ScholarBank@NUS Repository. https://doi.org/10.1124/dmd.111.041558||Abstract:||The preclinical absorption, distribution, metabolism, and excretion (ADME) properties of Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride; SB939], an orally active histone deacetylase inhibitor, were characterized and its human pharmacokinetics (PK) was predicted using Simcyp and allometric scaling. SB939 showed high aqueous solubility with high Caco-2 permeability. Metabolic stability was relatively higher in dog and human liver microsomes than in mouse and rat. The major metabolites formed in human liver microsomes were also observed in preclinical species. Human cytochrome P450 (P450) phenotyping showed that SB939 was primarily metabolized by CYP3A4 and CYP1A2. SB939 did not significantly inhibit human CYP3A4, 1A2, 2D6, and 2C9 (>25 μM) but inhibited 2C19 (IC 50 = 5.8 μM). No significant induction of human CYP3A4 and 1A2 was observed in hepatocytes. Plasma protein binding in mouse, rat, dog, and human ranged between ∼84 and 94%. The blood-toplasma ratio was ∼1.0 in human blood. SB939 showed high systemic clearance (relative to liver blood flow) of 9.2, 4.5, and 1.5 l · h -1 · kg -1 and high volume of distribution at steady state (>0.6 l/kg) of 3.5, 1.7, and 4.2 l/kg in mouse, rat, and dog, respectively. The oral bioavailability was 34, 65, and ∼3% in mice, dogs, and rats, respectively. The predicted oral PK profile and parameters of SB939, using Simcyp and allometric scaling, were in good agreement with observed data in humans. Simcyp predictions showed lack of CYP3A4 and 2C19 drug-drug interaction potential for SB939. In summary, the preclinical ADME of SB939 supported its preclinical and clinical development as an oral drug candidate. Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics.||Source Title:||Drug Metabolism and Disposition||URI:||http://scholarbank.nus.edu.sg/handle/10635/106237||ISSN:||00909556||DOI:||10.1124/dmd.111.041558|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 4, 2019
WEB OF SCIENCETM
checked on Dec 4, 2019
checked on Nov 30, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.